Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
about
STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumorsNGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostateIdentification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activityDetection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevancePSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusBioisosterism of urea-based GCPII inhibitors: Synthesis and structure–activity relationship studiesTumor immunotargeting using innovative radionuclidesDiscriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane AntigenIsolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase IINanoparticles for Improving Cancer Diagnosis.NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammationThe Maize Viviparous8 locus, encoding a putative ALTERED MERISTEM PROGRAM1-like peptidase, regulates abscisic acid accumulation and coordinates embryo and endosperm development.Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach.Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy.Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markersProstate-specific membrane antigen-based therapeutics.Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.Prostate-specific membrane antigen: evidence for the existence of a second related human genePET/CT Imaging and Radioimmunotherapy of Prostate CancerOptimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer.Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy.Isolation and characterization of circulating tumor cells in prostate cancer.SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.The homodimer of prostate-specific membrane antigen is a functional target for cancer therapyTargeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticlesPromoter analysis of human glutamate carboxypeptidase II.Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools.
P2860
Q22010908-EC5F8CE6-5E24-432E-829A-A3D6439F5FA6Q24311645-DCD8A98A-5781-4AD5-A548-75BC17D422C2Q24646415-E3C5FDB6-C339-4F56-B887-64DD525537FFQ24646761-443DFCD2-EE9E-409B-904E-61D7CB2F2C58Q26774920-0A986D06-4121-4326-AD92-7EACEEB9F692Q27658096-0D97B458-171C-496B-BC45-079C51A68D5BQ28083230-4A71BB9D-08AD-4CE8-B618-C25236CCABAEQ28533993-FD6B668C-78D2-4292-B08F-D20B7E0D6620Q28572589-4FD2D083-4622-45E9-B6DB-A62C09C77D8BQ30442412-C378B9CA-F431-4E8D-977A-7C41B176EAE6Q30459203-D1C39B16-8B33-41BC-ABF8-2537F0C80025Q33345087-6A95BBAA-58E6-4177-B151-A808CA2B899BQ33408024-6F787AB4-0BAA-4E1D-B1A4-C4D9CBDB78E8Q33576278-B7ED05CF-4989-4B60-BC20-D65F90344CD6Q33645821-3DA02E61-6A81-4C66-8FB4-8333BCD7DBE2Q33763004-BD01CA32-904C-4B72-A646-37FADE063ADDQ33899288-616C94C5-39B4-42CB-B173-AA014A60A9D3Q34016309-6ACD1755-2089-45CF-A4CC-5BEC0BF87ED7Q34073699-12DDF7B7-5A07-4360-B20A-48AF143F03D9Q34345914-820DCC6B-3F4D-42D8-AB99-01E5EA9EB905Q34429991-36B8AC5E-EA60-464F-A874-F622E31473E7Q34482756-95682E4D-5662-4534-8CE0-A7757D7D9037Q34550075-3A6CB187-ADDD-4BD7-B2E1-2CE3E93C98B7Q35032198-E05BA62F-482E-4B81-BA48-129F3B4EF787Q35132944-53149106-F912-4BB5-BCA4-BA455E23803CQ35169090-BA8F0382-3EAD-44E5-AC70-9BAD4A217DCBQ35256725-22E9629B-54AC-42A3-A30B-FA490CBA1001Q35948223-575C81A3-2DCC-40E2-83B3-F1B74BC0BF4EQ36010923-B856F614-7F9C-46E7-B4D5-BED0709BE562Q36081147-9F5F8834-9783-42D3-A76F-7169EAF4ED28Q36085426-406C36A5-3C89-4901-A145-731EBE0C1884Q36166095-D10C77AB-261E-4366-B9DE-A08F038AC2B5Q36291372-85CF47B5-1D3E-4487-9889-58FA9BD13D17Q36310363-3DD241FF-A1B7-44C3-B3C7-CE33CDA2D679Q36491182-F16EA38C-4226-4B18-BBCD-34A4A74912E5Q36501550-7340FC46-7289-4C7D-BABB-73BA61F61FF4Q36689474-40965C42-AD46-45AA-9ABF-2502778B8C93Q36970889-B5E16E4A-4CDD-426C-B752-354B0DF127C2Q37251428-4B999878-A18C-414A-B972-9A9B2FE53915Q37326960-3C2EC527-B9A5-4C9F-BF96-13EA4085B31E
P2860
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
description
1993 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1993
@ast
im Januar 1993 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1993/01/15)
@sk
vědecký článek publikovaný v roce 1993
@cs
wetenschappelijk artikel (gepubliceerd op 1993/01/15)
@nl
наукова стаття, опублікована в січні 1993
@uk
مقالة علمية (نشرت في 15-1-1993)
@ar
name
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@ast
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@en
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@nl
type
label
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@ast
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@en
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@nl
prefLabel
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@ast
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@en
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@nl
P2093
P3181
P1433
P1476
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
@en
P2093
P304
P3181
P407
P577
1993-01-01T00:00:00Z